• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助治疗后口腔鳞状细胞癌阳性淋巴结比率的预后价值:一项回顾性真实世界研究

Prognostic value of positive lymph node ratio in oral cavity squamous cell carcinoma after neoadjuvant treatment: a retrospective real-world study.

作者信息

Fan Sufeng, Cai Shunv, Cheng Yun, Wu Yimin, Jiang Wenmei

机构信息

Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China.

Department of Anaesthesiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, Banshan East Road, Gongshu District, Hangzhou, 310022, People's Republic of China.

出版信息

Sci Rep. 2025 May 22;15(1):17785. doi: 10.1038/s41598-025-03048-x.

DOI:10.1038/s41598-025-03048-x
PMID:40404864
Abstract

This study aimed to address the prognostic value of positive lymph node ratio for oral cavity squamous cell carcinoma (OCSCC) patients after neoadjuvant treatment, and build a prediction nomogram model. Patients with OCSCC with neoadjuvant treatment were retrieved from the Surveillance, Epidemiology, and End Results database from 2004 to 2021. The primary outcome was overall survival (OS), and the second outcome was disease-specific survival (DSS). Kaplan-Meier and log-rank tests were used to analyze the survival outcomes. Univariable and multivariable analyses were conducted, and then a nomogram was constructed. A total of 419 were included in this study. The optimal cutoff value of the positive lymph node ratio (LNR) was 7.0%. The 5-year OS of patients with low LNR was significantly improved over those with high LNR (p < 0.0001). LNR > 7.0% (HR 50.7, 95% CI 19.7-130.5), and unmarried status (HR 1.33, 95% CI 1.03-1.70) were the independent risk factors for OS (all p < 0.05). LNR > 7.0% (HR 35.8, 95% CI 9.63-132.7), gum primary site (HR 0.330, 95% CI 0.132-0.827), and preoperative chemotherapy and radiotherapy (HR 2.91, 95% CI 1.78-4.73) were the independent risk factors for DSS (all p < 0.05). According to the nomogram, patients were stratified into the high-risk group and the low-risk group for OS and DSS. Patients in the low-risk group were predicted with superior survival (both p < 0.05). The LNR was an independent prognostic factor of the OS and DSS for OCSCC patients after neoadjuvant treatment. The tools may be valuable to guide multidisciplinary teams in making treatment decisions.

摘要

本研究旨在探讨阳性淋巴结比率对口腔鳞状细胞癌(OCSCC)患者新辅助治疗后的预后价值,并建立预测列线图模型。从2004年至2021年的监测、流行病学和最终结果数据库中检索接受新辅助治疗的OCSCC患者。主要结局是总生存期(OS),次要结局是疾病特异性生存期(DSS)。采用Kaplan-Meier法和对数秩检验分析生存结局。进行单变量和多变量分析,然后构建列线图。本研究共纳入419例患者。阳性淋巴结比率(LNR)的最佳截断值为7.0%。LNR低的患者5年总生存期明显高于LNR高的患者(p<0.0001)。LNR>7.0%(HR 50.7,95%CI 19.7-130.5)和未婚状态(HR 1.33,95%CI 1.03-1.70)是总生存期的独立危险因素(所有p<0.05)。LNR>7.0%(HR 35.8,95%CI 9.63-132.

相似文献

1
Prognostic value of positive lymph node ratio in oral cavity squamous cell carcinoma after neoadjuvant treatment: a retrospective real-world study.新辅助治疗后口腔鳞状细胞癌阳性淋巴结比率的预后价值:一项回顾性真实世界研究
Sci Rep. 2025 May 22;15(1):17785. doi: 10.1038/s41598-025-03048-x.
2
Lymph node ratio-dependent prognosis stratification and postoperative radiotherapy utilization in T1-2N1 oral cavity carcinoma.T1-2N1 口腔癌中与淋巴结比值相关的预后分层及术后放疗应用。
Radiother Oncol. 2022 Jul;172:83-90. doi: 10.1016/j.radonc.2022.05.009. Epub 2022 May 12.
3
Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer.淋巴结比率与口腔癌患者复发和生存结局的关系。
JAMA Otolaryngol Head Neck Surg. 2019 Jan 1;145(1):53-61. doi: 10.1001/jamaoto.2018.2974.
4
Lymph node ratio (LNR) and lymph node yield (LNY) in head and neck cancer: A systematic review and meta-analysis.头颈部癌的淋巴结比率(LNR)和淋巴结收获量(LNY):一项系统评价与荟萃分析
J Craniomaxillofac Surg. 2025 Apr;53(4):290-300. doi: 10.1016/j.jcms.2024.11.016. Epub 2024 Dec 20.
5
The prognostic relevance of lymph node ratio in patients with oral squamous cell carcinoma treated with neoadjuvant therapy regimen and radical surgery.新辅助治疗方案联合根治性手术治疗口腔鳞状细胞癌患者中淋巴结比率的预后相关性。
J Craniomaxillofac Surg. 2018 Sep;46(9):1659-1663. doi: 10.1016/j.jcms.2018.05.053. Epub 2018 Jun 7.
6
Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.口腔癌中淋巴结比率与区域失败和远处转移的关系。
Radiother Oncol. 2017 Aug;124(2):225-231. doi: 10.1016/j.radonc.2017.06.018.
7
Association between lymph node ratio and survival outcomes in patients with oral squamous cell carcinoma.淋巴结比值与口腔鳞状细胞癌患者生存结局的关系。
J Stomatol Oral Maxillofac Surg. 2024 Jun;125(3S):101816. doi: 10.1016/j.jormas.2024.101816. Epub 2024 Mar 6.
8
Assessing Prognostic Value of Quantitative Neck Dissection Quality Measures in Patients With Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma.评估临床淋巴结阴性口腔鳞状细胞癌患者定量颈部清扫术质量指标的预后价值。
JAMA Otolaryngol Head Neck Surg. 2022 Oct 1;148(10):947-955. doi: 10.1001/jamaoto.2022.2312.
9
Lymph node ratio as an indicator of nodal status in the assessment of survival and recurrence in vulvar cancer: A cohort study.淋巴结比率作为评估外阴癌生存和复发的淋巴结状态指标:一项队列研究。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241285396. doi: 10.1177/17455057241285396.
10
Lymph node ratio as a prognostic factor in head and neck cancer patients.淋巴结比率作为头颈癌患者的一个预后因素。
Radiat Oncol. 2015 Aug 25;10:181. doi: 10.1186/s13014-015-0490-9.

本文引用的文献

1
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.隆突性皮肤纤维肉瘤,第1.2025版,美国国立综合癌症网络(NCCN)肿瘤学临床实践指南
J Natl Compr Canc Netw. 2025 Jan;23(1). doi: 10.6004/jnccn.2025.0001.
2
Marital status impacts survival of stage I non-small-cell lung cancer: a propensity-score matching analysis.婚姻状况对Ⅰ期非小细胞肺癌患者生存率的影响:一项倾向评分匹配分析。
Future Sci OA. 2024 May 15;10(1):FSO926. doi: 10.2144/fsoa-2023-0103. eCollection 2024.
3
Prognostic value of tumor deposits and positive lymph node ratio in stage III colorectal cancer: a retrospective cohort study.
肿瘤沉积和阳性淋巴结比率对 III 期结直肠癌预后的价值:一项回顾性队列研究。
Int J Surg. 2024 Jun 1;110(6):3470-3479. doi: 10.1097/JS9.0000000000001295.
4
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
5
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.免疫治疗时代的头颈部癌症治疗:2023 年更新。
Drugs. 2023 Feb;83(3):217-248. doi: 10.1007/s40265-023-01835-2. Epub 2023 Jan 16.
6
Relationship between lymph nodes examined and survival benefits with postoperative radiotherapy in oral cavity squamous cell carcinoma patients with stage T1-2N1M0.口腔鳞状细胞癌T1-2N1M0期患者术后放疗时检查淋巴结数量与生存获益之间的关系
Front Surg. 2022 Sep 28;9:928455. doi: 10.3389/fsurg.2022.928455. eCollection 2022.
7
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.评估多西他赛、顺铂和氟尿嘧啶新辅助化疗在口腔癌患者中的应用。
Cancer Med. 2023 Feb;12(3):2417-2426. doi: 10.1002/cam4.5075. Epub 2022 Jul 26.
8
Prediction of Long-Term Survival Outcome by Lymph Node Ratio in Patients of Parotid Gland Cancer: A Retrospective study.腮腺癌患者淋巴结比率对长期生存结果的预测:一项回顾性研究。
Front Surg. 2022 May 11;9:903576. doi: 10.3389/fsurg.2022.903576. eCollection 2022.
9
Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.前瞻性II期开放标签随机对照试验,比较可手术口腔癌 upfront 手术中保留下颌骨与新辅助化疗后手术的效果。
J Clin Oncol. 2022 Jan 20;40(3):272-281. doi: 10.1200/JCO.21.00179. Epub 2021 Dec 6.
10
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance).将肿瘤沉积物与淋巴结转移数相结合,以提高 III 期结肠癌的预后准确性:CALGB/SWOG 80702 期 III 研究(Alliance)的事后分析。
Ann Oncol. 2021 Oct;32(10):1267-1275. doi: 10.1016/j.annonc.2021.07.009. Epub 2021 Jul 20.